Healthcare Services

Advanced Melanoma Market Global Report 2026 Market Revenue Growth Expected to Reach $6.37 Billion by 2030 with 9.1% CAGR

March 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Advanced Melanoma Market Between 2026 And 2030?

The advanced melanoma market has shown substantial growth in recent years. It is anticipated to expand from $4.12 billion in 2025 to $4.5 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.3%. Historically, this growth can be attributed to factors such as limited therapeutic options for advanced stages, increasing incidence rates of melanoma, the expansion of hospital and oncology center infrastructure, enhanced awareness regarding skin cancer, and the adoption of conventional chemotherapy and biological therapies.

The advanced melanoma market is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $6.37 billion by 2030, showing a compound annual growth rate (CAGR) of 9.1%. This expansion during the forecast period can be attributed to advancements in immune checkpoint inhibitors, the increasing application of targeted therapies such as BRAF and MEK inhibitors, the broadening of personalized medicine approaches, rising investment in melanoma research, and the integration of digital health and patient monitoring solutions. Significant trends expected during this period include the growing uptake of immunotherapy and targeted therapies, an increased reliance on biomarker-based treatment selection, the enhancement of hospital and oncology center capabilities, a heightened focus on early detection and diagnostic tools, and an escalation in clinical trials and research concerning advanced melanoma.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21088&type=smp

What Major Drivers Are Influencing Demand In The Advanced Melanoma Market?

An increasing frequency of severe sunburn cases is anticipated to fuel the expansion of the advanced melanoma market in the coming years. Severe sunburns are intense skin burns caused by excessive exposure to ultraviolet (UV) radiation, leading to symptoms such as redness, pain, swelling, and sometimes blistering. The rise in severe sunburn incidents is due to prolonged exposure to ultraviolet (UV) radiation, insufficient sun protection, more outdoor activities during peak UV hours, and rising temperatures linked to climate change. Such sunburns, especially if repeated or occurring at a young age, cause DNA damage in skin cells, potentially leading to genetic mutations that trigger melanoma. For instance, in May 2024, according to Melanoma Focus, a UK-based charity dedicated to supporting the melanoma community, during 2022-23, there were 201 hospital admissions due to sunburn, including 89 children and 25 babies under one-year-old. Furthermore, 66% of UK adults aged 16-65 recollected getting sunburned as children, and 65% experienced severe sunburn with blisters at least once. This proportion increased to 77% for those with light, pale, or white skin. Therefore, the growing number of severe sunburn cases is actively driving the growth of the advanced melanoma market.

Which Market Segments Are Examined In The Advanced Melanoma Market Study?

The advanced melanoma market covered in this report is segmented –

1) By Therapeutics: Chemotherapy, Biological Therapy, Targeted Therapy, Immune Therapy

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

3) By End-User: Hospitals, Cancer Research Centres, Academic Institutes, Diagnostic Centers, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Chemotherapy: Alkylating Agents, Antimetabolites, Topoisomerase Inhibitors, Other Chemotherapy Drugs

2) By Biological Therapy: Monoclonal Antibodies, Interferons, Interleukins

3) By Targeted Therapy: BRAF Inhibitors, MEK Inhibitors, KIT Inhibitors, Other Targeted Therapies

4) By Immune Therapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Oncolytic Virus Therapy, Adoptive Cell Transfer

Which Trends Are Influencing The Advanced Melanoma Market?

Major companies in the advanced melanoma market are focused on developing innovative products, such as personalized vaccines, to enhance treatment efficacy, overcome resistance mechanisms, and provide tailored treatment options that can lead to better patient outcomes and prolonged survival. A personalized vaccine for advanced melanoma is a type of cancer treatment specifically designed for an individual patient based on the unique genetic mutations within their tumor. For instance, in April 2023, Merck & Co. Inc., a US-based pharmaceutical company, and Moderna Inc., a US-based biotechnology company, received Priority Medicines (PRIME) scheme designation from the European Medicines Agency (EMA) for their investigational personalized mRNA cancer vaccine, mRNA-4157/V940, when utilized in combination with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for the adjuvant treatment of patients with high-risk stage III/IV melanoma following complete resection. The personalized cancer vaccine mRNA-4157/V940 consists of a single synthetic mRNA coding for up to 34 neoantigens and is developed and produced based on the unique mutational signature of the patient’s tumor.

Who Are The Primary Competitors In The Advanced Melanoma Market?

Major companies operating in the advanced melanoma market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb, AstraZeneca AG, Novartis AG, Amgen Inc., BioNTech SE, Regeneron Pharmaceuticals, Genentech Inc., Exelixis Inc., Dynavax Technologies, Replimune Group, Immunocore Holdings plc, Xencor Inc., Agenus Inc., Nektar Therapeutics, Iovance Biotherapeutics, Adaptimmune Therapeutics, Immutep Ltd., Lytix Biopharma

Read the full advanced melanoma market report here:

https://www.thebusinessresearchcompany.com/report/advanced-melanoma-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Advanced Melanoma Market?

North America was the largest region in the advanced melanoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced melanoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Advanced Melanoma Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21088&type=smp

Browse Through More Reports Similar to the Global Advanced Melanoma Market 2026, By The Business Research Company

malignant melanoma treatment global market report

https://www.thebusinessresearchcompany.com/report/malignant-melanoma-treatment-global-market-report

melanoma drugs global market report

https://www.thebusinessresearchcompany.com/report/melanoma-drugs-global-market-report

metastatic melanoma therapeutics global market report

https://www.thebusinessresearchcompany.com/report/metastatic-melanoma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795